Introdução: A cardiomiopatia dilatada é uma das principais causas de insuficiência cardíaca com alta morbidade e mortalidade. Alterações genéticas em mais de 29 genes já foram relacionadas com a doença, contudo, elas explicam apenas uma pequena porcentagem dos casos sugerindo haver então outros genes relacionados com a doença. Foram relacionados para o presente projeto quatro genes candidatos, previamente relacionados com outras doenças cardíacas, para verificação de uma possível associação com a cardiomiopatia dilata idiopática. Objetivos: Avaliar a presença e frequência de mutações nos genes ACTC1, CSRP3, FKBP1A e FKBP1B de pacientes com cardiomiopatia dilatada do Instituto do Coração de São Paulo (InCor, FMUSP), investigar se há correlações entre o genótipo e o fenótipo e estudar as alterações funcionais desencadeadas pelas mutações encontradas. Métodos: Amostras de DNA de 186 pacientes com cardiomiopatia dilatada idiopática foram selecionados de um banco de dados do Instituto do Coração e triados geneticamente para alterações nos genes selecionados. Resultados e Discussão: Foram encontradas nove novas variantes genéticas. Cinco delas também estavam presentes no grupo controle, sendo excluídas como causativas da doença. Três delas não estavam presentes no grupo controle, contudo, dados de bioinformática avaliaram as alterações com um risco baixo de serem causativas. Uma alteração no gene CSRP3, que levava a troca de aminoácido, não estava presente no grupo controle e apresentou dados indicativos de mutação causativa da doença. Lâminas cardíacas foram avaliadas para verificação de possíveis dos mecanismos de ação, contudo, houve apenas a exclusão de alguns mecanismos previamente descritos na literatura. Conclusões: Não há evidências de que as alterações nos genes ACTC1, FKBP1A e FKBP1B estariam associadas com o desenvolvimento da doença. A alteração no gene CSRP3 também é capaz de causar cardiomiopatia dilatada idiopática / Introduction: Dilated Cardiomyopathy is one of the leading causes of heart failure with high morbidity e mortality. Already known genetic alterations explain little percentage of cases suggesting that other genes would be related with the disease. Four candidates genes previously related with other cardiac diseases were selected for the project to verify a possible relationship with dilated cardiomyopathy. Objectives: Evaluate the presence and frequency of genetic alterations in ACTC1, FKBP1A, FKBP1B and CSRP3 genes in dilated cardiomyopathy patients of São Paulo Heart Institute (Incor, FMUSP). To investigate for genotype/phenotype correlations and to study functional alterations triggered by the found mutations. Methods: DNA samples from 186 patients with dilated cardiomyopathy were selected from the Incor DNA bank and genetically screened for alterations in the selected genes. Results and Discussion: Nine new genetic variants were found. Five of them were present in the control population, thus being excluded as disease causative. Three of them were not present in the control population; however, bioinformatics analysis evaluated the alterations having a low risk of being causatives. One alteration in CSRP3 gene that resulted in amino-acid change was not present in control population and exhibit indicative data of disease causing mutation. Analysis of patient heart showed no difference from some disease mechanisms described in literature. Conclusions: There are no evidences that alterations in ACTC1, FKBP1A and FKBP1B genes would associated with disease development. Alteration in CSRP3 gene is also capable to cause dilated cardiomyopathy s

Introdução: A cardiomiopatia dilatada é uma das principais causas de insuficiência cardíaca com alta morbidade e mortalidade. Alterações genéticas em mais de 29 genes já foram relacionadas com a doença, contudo, elas explicam apenas uma pequena porcentagem dos casos sugerindo haver então outros genes relacionados com a doença. Foram relacionados para o presente projeto quatro genes candidatos, previamente relacionados com outras doenças cardíacas, para verificação de uma possível associação com a cardiomiopatia dilata idiopática. Objetivos: Avaliar a presença e frequência de mutações nos genes ACTC1, CSRP3, FKBP1A e FKBP1B de pacientes com cardiomiopatia dilatada do Instituto do Coração de São Paulo (InCor, FMUSP), investigar se há correlações entre o genótipo e o fenótipo e estudar as alterações funcionais desencadeadas pelas mutações encontradas. Métodos: Amostras de DNA de 186 pacientes com cardiomiopatia dilatada idiopática foram selecionados de um banco de dados do Instituto do Coração e triados geneticamente para alterações nos genes selecionados. Resultados e Discussão: Foram encontradas nove novas variantes genéticas. Cinco delas também estavam presentes no grupo controle, sendo excluídas como causativas da doença. Três delas não estavam presentes no grupo controle, contudo, dados de bioinformática avaliaram as alterações com um risco baixo de serem causativas. Uma alteração no gene CSRP3, que levava a troca de aminoácido, não estava presente no grupo controle e apresentou dados indicativos de mutação causativa da doença. Lâminas cardíacas foram avaliadas para verificação de possíveis dos mecanismos de ação, contudo, houve apenas a exclusão de alguns mecanismos previamente descritos na literatura. Conclusões: Não há evidências de que as alterações nos genes ACTC1, FKBP1A e FKBP1B estariam associadas com o desenvolvimento da doença. A alteração no gene CSRP3 também é capaz de causar cardiomiopatia dilatada idiopática / Introduction: Dilated Cardiomyopathy is one of the leading causes of heart failure with high morbidity e mortality. Already known genetic alterations explain little percentage of cases suggesting that other genes would be related with the disease. Four candidates genes previously related with other cardiac diseases were selected for the project to verify a possible relationship with dilated cardiomyopathy. Objectives: Evaluate the presence and frequency of genetic alterations in ACTC1, FKBP1A, FKBP1B and CSRP3 genes in dilated cardiomyopathy patients of São Paulo Heart Institute (Incor, FMUSP). To investigate for genotype/phenotype correlations and to study functional alterations triggered by the found mutations. Methods: DNA samples from 186 patients with dilated cardiomyopathy were selected from the Incor DNA bank and genetically screened for alterations in the selected genes. Results and Discussion: Nine new genetic variants were found. Five of them were present in the control population, thus being excluded as disease causative. Three of them were not present in the control population; however, bioinformatics analysis evaluated the alterations having a low risk of being causatives. One alteration in CSRP3 gene that resulted in amino-acid change was not present in control population and exhibit indicative data of disease causing mutation. Analysis of patient heart showed no difference from some disease mechanisms described in literature. Conclusions: There are no evidences that alterations in ACTC1, FKBP1A and FKBP1B genes would associated with disease development. Alteration in CSRP3 gene is also capable to cause dilated cardiomyopathy s

We hypothesized that alterations in cardiac myofilaments are associated with hereditary canine DCM. DCM myofilaments demonstrated a reduction in EC50 and a modest decrease in maximum activity compared to non-failing dog samples. Treatment of myofilaments with the calcium sensitizer, bepridil, showed a reduction in EC50. Desmin and tropomyosin phosphorylation was increased in DCM. Desmin protein levels were increased in DCM. Total troponin I phosphorylation was unchanged, but S23/S24 phosphorylation was reduced in DCM. Myofilament-associated PKC-δ and -ζ were elevated in DCM, PKC- ε was modestly reduced, and PKC-α showed no change. These data are the first investigation of cardiac myofilaments in naturally occurring canine DCM, and support the hypothesis that alterations in cardiac myofilaments are associated with DCM. / OVC Pet Trust (operating funds)

Integrin-linked kinase (ILK) is an important mechanoreceptor that mediates many cellular signaling pathways. Its dysregulation causes dilated cardiomyopathy and other complications in the heart. Restoration of ILK improves cardiac function and survival, but the exact mechanism is unknown. Recent studies in our lab suggest that the cardioprotective properties of ILK may be related to its regulation of sarco/endoplasmic reticulum calcium ATPase (SERCA2a). The protein expressions of ILK and SERCA2a are positively correlated based on adenoviral transduction of ILK and siRNA targeting ILK in human induced pluripotent stem cell-derived cardiomyocytes. From analysis of their calcium transients, ILK transduction resulted in increased beat rate and faster calcium clearance while siRNA knockdown produced the opposite effect. The use of SERCA-specific inhibitor thapsigargin nullified the observed effects of ILK transduction. Based on these results, we conclude that ILK’s cardioprotective properties are partly related to improving calcium handling in cardiomyocytes through the regulation of SERCA2a.

Integrin-linked kinase (ILK) is an important mechanoreceptor that mediates many cellular signaling pathways. Its dysregulation causes dilated cardiomyopathy and other complications in the heart. Restoration of ILK improves cardiac function and survival, but the exact mechanism is unknown. Recent studies in our lab suggest that the cardioprotective properties of ILK may be related to its regulation of sarco/endoplasmic reticulum calcium ATPase (SERCA2a). The protein expressions of ILK and SERCA2a are positively correlated based on adenoviral transduction of ILK and siRNA targeting ILK in human induced pluripotent stem cell-derived cardiomyocytes. From analysis of their calcium transients, ILK transduction resulted in increased beat rate and faster calcium clearance while siRNA knockdown produced the opposite effect. The use of SERCA-specific inhibitor thapsigargin nullified the observed effects of ILK transduction. Based on these results, we conclude that ILK’s cardioprotective properties are partly related to improving calcium handling in cardiomyocytes through the regulation of SERCA2a.

La cardiomyopathie dilatée est l'une des principales causes d'insuffisance cardiaque en Europe. Dans le cadre de la cardiomyopathie liée aux mutations du gène LMNA, en dépit des soins médicaux conventionnels, aucun traitement satisfaisant ne permet de pallier à la dilatation cardiaque progressive et à la perte de la contractilité. Le gène LMNA code pour les lamines nucléaires de type A, qui sont les principaux constituants de la lamina nucléaire. De précédents travaux démontrent que l'activation anormale de ERK 1/2 est impliquée dans la pathophysiologie de la cardiomyopathie dilatée liée aux mutations du gène LMNA. L'inhibition de la voie ERK 1/2 ralentit également la progression de la fibrose myocardique, relativement développée chez l'homme, en cas de cardiomyopathie dilatée. Dans le cadre de ma thèse, j’ai suggéré que l'activité aberrante de la voie TGF-β pourrait participer à l’activation anormale de ERK 1/2 et être impliquée dans la physiopathologie de dysfonction contractile ventriculaire gauche dans la cardiomyopathie liée aux mutations du gène LMNA. Les mécanismes moléculaires sous-jacents à la modulation de la signalisation ERK1/2, causée dans le cœur, par les mutations du gène LMNA, restent totalement incertains. De ce fait, j'ai testé l'hypothèse selon laquelle la modulation anormale de ERK1/2 induirait l'altération des cibles cytosoliques et modifierait le réseau du cytosquelette cardiaque. Mon travail a mis en évidence un nouveau partenaire de la forme active (phosphorylée) d’ERK1/2 : cofiline-1. La cofiline induit la déramification des filaments d'actine. Ce projet met en lumière un rôle inattendu joué par la signalisation ERK1/2 dans la dynamique de l'actine et dans le développement de la dysfonction ventriculaire gauche de la cardiomyopathie liée aux mutations du gène LMNA. / Dilated cardiomyopathy is one of the leading causes of heart failure in Europe. Despite of the conventional medical care, there is no definitive treatment for the progressive cardiac dilatation and loss of contractility in LMNA cardiomyopathy often leading to sudden death or heart transplantation. LMNA gene encodes nuclear A-type lamins, which are the main constituents of the nuclear lamina. Previous studies clearly show that the abnormal ERK1/2 activation is involved in the pathophysiology of LMNA dilated cardiomyopathy. However, its role in the development of cardiac dysfunction remains unclear. Inhibition of ERK1/2 signaling also slows progression of myocardial fibrosis, which is prominent in humans with dilated cardiomyopathy. I suggested that aberrant TGF-β signaling activity could participate to the abnormal ERK1/2 activation and be involved is the pathophysiology of left-ventricular contractile dysfunction in LMNA cardiomyopathy. Given that the understanding of molecular and cellular mechanisms underlying the modulation of ERK1/2 signaling in the heart caused by LMNA mutation remains totally unclear, I tested the hypothesis that ERK1/2 abnormal modulation leads to alteration of cytosolic targets and alter cardiac cytoskeleton network. My work highlighted a novel partner of activated (phosphorylated) ERK1/2, ADF/cofilin-1. Cofilin promotes debranching of actin filaments. I showed that disrupted actin dynamics leads to abnormal sarcomere structure. This project unraveled an unexpected role played by ERK1/2 signaling in actin dynamics and in the development of left-ventricular dysfunction in LMNA cardiomyopathy.

Introduction: Inflammatory cardiomyopathy (DCMi) represents a non-familial form of dilated cardiomyopathy (DCM) and endomyocardial biopsy (EMB) is crucial for its diagnosis. Aims: To assess the prevalence of DCMi in patients with DCM of unclear origin, to evaluate the significance of serological tests for antibodies against infectious cardiotrophic agents and to analyze the effect of specific therapy guided by EMB results. Methods: EMB was performed in 56 subjects (mean age 52 ± 10 years) with DCM of unclear etiology and left ventricular (LV) ejection fraction (EF) < 40% with a history of heart failure less than 1 year. EMB samples were analyzed by immunohistochemistry, polymerase chain reaction (PCR) and electron microscopy. Results: Immunohistochemical examination revealed myocardial inflammation in 26 patients (46%), the PCR method detected genome of microbial agents in 32 patients (57%). Electron microscopy showed the presence of particles of microbial agents in 41 patients (73%). Serological blood tests found no IgM antibody positivity against any of the investigated microbial agents. Targeted antibiotic therapy in patients with evidence of Borrelia burgdorferi (Bb) genome in the EMB led to a reduction in LV size, improvement of LV EF and alleviate symptoms of heart failure. Conclusion: DCMi...

A proteína S100B é considerada um marcador bioquímico para lesão cerebral. Entretanto, foi demonstrado que há liberação de S100B em coração isolado de rato. Neste estudo, investigou-se os níveis séricos de S100B em pacientes portadores de cardiomiopatia dilatada (CMD). Métodos e Resultados: Foram selecionados 21 pacientes com CMD, excluindo qualquer condição que pudesse influenciar os níveis séricos de S100B. O grupo controle foi composto por 21 indivíduos pareados por sexo e idade. Ambos os grupos foram submetidos à avaliação clínica, ecocardiográfica, mensuração da proteína S100B e de NT-proBNP (expressos como mediana [variação interquartil]). Os níveis de NT-proBNP no grupo de pacientes (1462 pg/ml [426 - 3591]) foram maiores do que no grupo controle (35 pg/ml [29 - 55]); P<0.001. Os níveis de S100B foram maiores no grupo de pacientes (0.051µg/L [0.022 - 0.144]) do que no grupo controle (0.017µg/L [0.003 - 0.036]); P=0.009. Houve correlação positiva entre os níveis séricos de S100B e NT-proBNP somente no grupo de pacientes (Coeficiente de Spearman r=0.534; P=0.013). Conclusão: A proteína S100B está aumentada na CMD. Embora não possamos excluir a influência de dano cerebral, houve uma correlação positiva entre os níveis séricos de S100B e NT-proBNP em pacientes com CMD / The S100B protein is considered a biochemical marker for brain injuries. However, the isolated rat heart releases S100B. In this study, the serum levels of S100B was investigated in dilated cardiomyopathy (DCM) patients in order to evaluate its levels in heart disease. Methods and Results: It was selected DCM patients, excluding any condition that could influence S100B serum levels. Control individuals were sex and age matched. Both groups were submitted to clinical evaluation and echocardiography. The S100B and NT-proBNP serum levels (expressed as median [interquartile range]) were measured. NT-proBNP levels in patients group (1462 pg/ml [426 - 3591]) were higher than in controls (35 pg/ml [29 - 55]); P<0.001. S100B serum levels were higher in patients group (0.051µg/L [0.022 - 0.144]) than in controls (35 pg/ml [29 - 55]); P<0.001. S100B serum levels were higher in patients group (0.051µg/L [0.022 - 0.144]) than in controls (0.017µg/L [0.003 - 0.036]); P=0.009. Additionally, a positive correlation between S100B and NT-proBNP serum levels only in patients group (Spearman\'s coefficient r=0.534; P=0.013) was found . Conclusions: Although the influence of S100B from brain cannot rule out, the positive correlation between S100B and NT-proBNP levels in DCM patients points to the myocardium as the main source for the rise in S100B serum levels

A cardiomiopatia dilatada (CMD) é uma doença freqüente na clínica veterinária que acomete, principalmente, a espécie canina, habitualmente os machos, jovens ou adultos-jovem, das raças grandes e gigantes, em especial Doberman e Boxer. A doença caracteriza-se por uma redução na contratilidade e, freqüentemente, por arritmias que resultam na diminuição do volume sistólico e do débito cardíaco. O tratamento convencionalmente preconizado para cães acometidos pela CMD consiste na prescrição de vasodilatadores, agentes inotrópicos positivos (digitálico), diuréticos, dieta hipossódica e, quando necessário, antiarrítmicos. A ativação do sistema nervoso simpático (SNAS) ocorre em resposta à redução do débito cardíaco e da pressão arterial observados em casos de insuficiência cardíaca. Porém a partir de um certo grau os efeitos hipertensivos, cronotrópicos e inotrópicos positivos do SNAS geram graves alterações cardíacas como a sobrecarga de pressão e volume nos ventrículos, conseqüente isquemia miocárdica, morte de miócitos com deposição de tecido conjuntivo, diminuição da contratilidade cardíaca e nova sobrecarga de pressão e volume. O carvedilol é um &beta;-bloqueador de 3a geração, não seletivo, que bloqueia igualmente e competitivamente os receptores &beta;1, &beta;2 e &beta;1. O carvedilol produz uma evidente vasodilatação periférica, exerce efeitos anti-oxidantes, removendo radicais livres de oxigênio e prevenindo a peroxidação lipídica nas membranas cardíacas, prevenindo a perda de miócitos e a ocorrência de arritmias e reduzindo a taxa de mortalidade em pacientes humanos. O objetivo do presente estudo foi avaliar clínica, eletrocardiográfica, radiográfica e ecocardiograficamente a evolução de cães com cardiomiopatia dilatada (CMD) tratatos com terapia convencional associada ao carvedilol. Para tal foram avaliados 49 cães com CMD divididos em: grupo NT, tratado com terapia convencional, e grupo T, tratado com terapia convencional associada ao carvedilol. Os animais foram submetidos à avaliação clínica e a exames complementares durante o período de um ano. Os resultados demonstraram que a terapia com carvedilol apresentou boa tolerabilidade na dose de 0,3 mg/kg/12-12horas, aumentou a sobrevida dos cães em 30,9%, não alterou as pressões sistólica e diastólica, reduziu a freqüência cardíaca após três semanas de terapia, melhorou significantemente as frações de encurtamento e ejeção após seis meses de tratamento, não promoveu alterações radiográficas e da distância E-septo, diminuiu o índice de letalidade da doença, fato demonstrado pela melhora no escore clínico e na classe funcional dos animais, obtidas após três semanas de terapia com carvedilol. / Dilated cardiomyopathy (DCM) is a frequent disease in veterinary clinics which occurs specially in dogs, mostly males, young or young-adults, of big and giant breeds, mainly Dobermans and Boxers. The disease is characterized by a reduction in contractility and, frequently, by arrhythmias resulting in decrease of systolic volume and cardiac output. Commonly prescribed therapy for dogs presenting DCM consists of vasodilators, positive inotropic drugs (digitalics), diuretics, low-sodium diet and, when necessary, anti-arrhythmics. Activation of sympathetic nervous system (SNS) occurs in response to decrease in cardiac output and arterial pressure observed in cases of heart failure. However, after a certain degree, hypotensive, chronotropic and positive inotropic effects of SNS lead to severe heart alterations like pressure and volume overload on ventricles with consequent myocardial ischemia, death of myocytes with connective tissue deposition, decrease in heart contractility, and again pressure and volume overload. Carvedilol is a third generation non-selective ?- blocker which blocks equally and competitively &beta;1, &beta;2 and &beta;1 receptors. Carvedilol produces an evident peripheral vasodilation, exerts anti-oxidative effects, removing free radicals of oxygen and preventing lipidic peroxydation of cardiac membranes, and the loss of myocytes and arrhythmias, as well as reducing mortality rate in human patients. The aim of the present study was to evaluate by physical examination, electrocardiography, radiography, and echocardiography the evolution of dogs with dilated cardiomyopathy (DCM) treated by conventional therapy associated to carvedilol. Forty-nine dogs with DCM were divided in two groups: group NT: treated with conventional therapy, and group T: treated with conventional therapy associated to carvedilol. The animals were submitted to clinical and complementary examinations during one year. The results demonstrated that carvedilol therapy presented good tolerability on the dose of 0,3 mg/Kg each 12 hours, prolonged lifetime of the dogs in 30,9%, did not alter systolic or diastolic pressure, reduced heart frequency after three weeks of treatment, significantly enhanced shortening and ejection fractions after six months of treatment, did not promote radiographic or E-septum distance alterations, decreased patients letality, as demonstrated by improvement of clinical score and functional class (heart failure according to NYHA) of the animals, obtained three weeks after the beginning of cavedilol therapy.

Cardiomiopatia dilatada (CMD) é uma das doenças cardiovasculares adquiridas mais comuns em cães afetando principalmente cães de raças grandes e gigantes, além do Cocker Spaniel Inglês e Americano. A anormalidade primária é a diminuição da contratilidade miocárdica, com dilatação secundária das câmaras cardíacas, que pode evoluir para insuficiência cardíaca, apresentar arritmias (atrial e/ou ventricular) e resultar em óbito em qualquer estágio da doença (sendo a morte súbita relativamente comum). Poucos estudos em cães, sendo a maioria retrospectiva, têm o objetivo de determinar fatores prognósticos, e predizer o prognóstico em qualquer paciente continua a ser um desafio. Portanto, no presente trabalho objetivou-se estudar a sobrevida de cães com CMD, assim como observar possíveis fatores determinantes de sobrevida. Para tal, foram avaliados 50 cães com CMD por meio de exame físico, radiográfico de tórax, eletrocardiográfico (eletrocardiograma de repouso e monitorização Holter) e ecocardiográfico. Os animais foram acompanhados por pelo menos 150 dias ou até o óbito. Avaliou-se a influência da idade, raça, sexo, fração de encurtamento do ventrículo esquerdo (FE), da classe funcional da insuficiência cardíaca, da presença de ascite, efusão pleural, edema pulmonar, insuficiência cardíaca bilateral, fibrilação atrial (FA) ou de arritmias ventriculares na sobrevida. A sobrevida dos cães com CMD variou de cinco dias a 1021 dias, com tempo médio de 347 dias, e tempo mediano de sobrevida foi de 223 dias; a probabilidade de sobreviver por seis meses foi de 51%, por um ano foi de 37% e por dois anos foi de 13%. Os cães da raça Cocker Spaniel Inglês apresentaram maior sobrevida em relação aos cães da raça Doberman e aos cães de outras raças. A presença de FA (p<0,03) e de arritmias ventriculares (tanto de ectopias ventriculares no eletrocardiograma de repouso (p<0,02) como de taquicardia ventricular não sustentada (p<0,0001) na monitorização Holter) foram associadas a menor sobrevida, enquanto que a idade, FE, sexo, classe funcional da insuficiência cardíaca, presença de ascite, efusão pleural, edema pulmonar ou insuficiência cardíaca bilateral não estiveram associados a aumento da mortalidade. A sobrevida foi variável, mas o prognóstico em geral foi ruim. O melhor preditor diagnóstico foi a presença de taquicardia ventricular não sustentada na monitorização Holter. / Dilated cardiomyopathy (DCM) is one of the most common acquired cardiovascular disease of dogs, affecting mainly large and giant breeds, as well as English and American Cocker Spaniels. The primary abnormality is decrease in myocardial contractility with secondary cardiac chambers dilatation. The clinical presentation may include development of heart failure, arrhythmias (atrial and/or ventricular), and death in any phase of the disease (with sudden death relatively frequent). Few studies have been described in dogs with the purpose of determining prognostic indicators for DCM, and predicting prognosis in any given single patient continues to be a challenge. The aim of this study was to evaluate survival time, and if possible, to find factors influencing prognosis in dogs with dilated cardiomyopathy. Fifty dogs with DCM have been included in the study. The patients were prospectively evaluated by physical examination, ten-lead electrocardiography, thoracic radiography, 24-hour Holter monitoring, and echocardiography. The animals were followed-up for at least 150 days or until death. Studied variables were left ventricle shortening fraction, age, sex, breed, presence of ascite, subcutaneous edema, pulmonary edema, pleural effusion, biventricular heart failure, as well as, presence of atrial fibrillation and ventricular arrhythmias, including non-sustained ventricular tachycardia on Holter monitoring. The mean and median survival time were, respectively, 347 days and 223 days (range 5 to 1021 days). Probability of survival at six months was 51%, at 1 year was 37%, and at 2 year was 13%. The survival time was significantly longer in English Cocker Spaniel, versus Doberman Pinschers, or versus other breeds. Atrial fibrillation (p<0,03) and ventricular arrhthmias (ventricular ectopy on ten-lead electrocardiography (p<0,02) and non-sustained ventricular tachycardia (p<0,0001) on Holter monitoring) were associated with increased mortality. While age at the time of presentation, shortening fraction, gender, presence of ascites, pleural effusion, or pulmonary edema were not associated with increased mortality. Survival time was variable, but the prognosis was usually poor. The best prognostic indicator was the presence of non-sustained ventricular tachycardia in Holter monitoring.